CRWD Research Update — September 20, 2026 (Updated)
Updated Thesis
CrowdStrike Holdings is a cloud-native cybersecurity platform company that sells subscriptions to its Falcon platform and a growing array of cloud modules spanning endpoint protection, cloud workload security, identity protection, Next-Gen SIEM, threat intelligence, and managed services, generating revenue through a direct sales force and channel partners from its Austin, Texas headquarters with roughly 11,706 employees. The business quality is genuinely high on the top line: revenue grew 25.8% year over year in the most recent quarter, TTM gross margin is 75.2%, and Next-Gen SIEM ARR has surpassed $695 million as platform adoption and tool consolidation drive larger security deals, while the company was named a Leader in The Forrester Wave: Proactive Security Platforms, Q3 2026, ranking highest of all vendors in the Strategy category with maximum scores in four criteria including Innovation and Roadmap. The problem is profitability and price: TTM operating margin is -2.2%, TTM net margin is 1.1%, ROE is just 1.3%, and the shares trade at 49.0 times sales, 167.93 times free cash flow, 595.66 times EV/EBITDA, and a trailing P/E of 4,518.35, placing the stock in a very expensive regime versus its own five-year history.
The investment grade as of this refresh is C — average business quality. A-tier business, D-tier valuation with 13.1% downside to $225.56 fair value.
Key Metrics at a Glance
- Revenue growth: +25.8% year over year
- Net margin: 1.1%
- Fair value upside: -13.1% to our estimate of $226
Current price: $259.67
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. CrowdStrike Holdings, Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full CRWD research →](/stocks/CRWD)